New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia

INTRODUCTION: Chagas disease (CD) affects ~7 million people worldwide. Benznidazole (BZN) and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both drugs are highly effective in acute and paediatric infections, their efficacy in adults with chronic CD (CCD) is lower and var...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso-Vega, Cristina, Urbina, Julio A, Sanz, Sergi, Pinazo, María-Jesús, Pinto, Jimy José, Gonzalez, Virginia R, Rojas, Gimena, Ortiz, Lourdes, Garcia, Wilson, Lozano, Daniel, Soy, Dolors, Maldonado, Rosa A, Nagarkatti, Rana, Debrabant, Alain, Schijman, Alejandro, Thomas, M Carmen, López, Manuel Carlos, Michael, Katja, Ribeiro, Isabela, Gascon, Joaquim, Torrico, Faustino, Almeida, Igor C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720984/
https://www.ncbi.nlm.nih.gov/pubmed/34972765
http://dx.doi.org/10.1136/bmjopen-2021-052897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720984/
https://www.ncbi.nlm.nih.gov/pubmed/34972765
http://dx.doi.org/10.1136/bmjopen-2021-052897

Ejemplares similares